Lensar Share Slide on Terminated Merger Deal With Alcon
By Adriano Marchese
Shares of Lensar fell sharply Tuesday after the medical-device company said it won't go forward with its merger with Alcon over concerns the deal wouldn't pass regulatory scrutiny before the pact's deadline.
Shares were trading 30% lower at $7.18, easing from a 52-week low of $6.77 earlier in the morning.
Lensar said late Monday that the companies terminated their deal after concluding they wouldn't secure U.S. regulatory approvals from the Federal Trade Commission in time to close it. The merger agreement was set to expire April 23, with an option to extend to July 23.
The deal was originally signed in March of last year when Alcon agreed to acquire Lensar in a deal worth about $430 million, or $14 a share.
Lensar said it will retain the $10 million deposit contemplated by the merger agreement.
Alcon shares fell 0.6% to $77.32.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 17, 2026 10:42 ET (14:42 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
